A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo

BACKGROUND: Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulin- mediated suppression of hepatic glucose output and tissue glucose disposal. In such ani...

Full description

Saved in:
Bibliographic Details
Main Authors: Scranton, Richard E, Gaziano, J Michael, Rutty, Dean, Ezrokhi, Michael, Cincotta, Anthony
Format: Artigo
Language:Inglês
Published: BioMed Central 2007
Subjects:
Study Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1924849/
https://ncbi.nlm.nih.gov/pubmed/17592632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6823-7-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items